Log In Sign up
The largest database of trusted experimental protocols

Lupron

Manufactured by Abbvie
Visit Supplier
Sourced in United States

Lupron is a prescription medication primarily used for the treatment of certain medical conditions. It contains the active ingredient leuprolide acetate, which is a synthetic analogue of the naturally occurring gonadotropin-releasing hormone (GnRH). Lupron functions by suppressing the production of certain hormones, such as testosterone and estrogen, in the body.

Automatically generated - may contain errors

Lab products found in correlation

Follistim, by Merck Group (1 mentions) Ganirelix, by Merck Group (1 mentions) Ovidrel, by Merck Group (1 mentions) Cetrotide, by Merck Group (1 mentions) Gonal f, by Merck Group (1 mentions) Novarel, by Ferring (1 mentions) Estrace, by Abbvie (1 mentions) Pregnyl, by Merck Group (1 mentions)

4 protocols using lupron

1

Controlled Ovarian Hyperstimulation Protocols for IVF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients underwent standard COH for IVF either with a down-regulation protocol with leuprolide acetate (Lupron®, AbbVie Inc., North Chicago, IL), an antagonist protocol (Ganirelix Acetate®, Organon USA Inc., Roseland, NJ or Cetrotide®, EMD Serono, Rockland, MA) or a Microflare protocol (Lupron®, AbbVie Inc., North Chicago, IL). Final oocyte maturation was induced with r-hCG alone (Ovidrel®, EMD Serono, Rockland, MA) or, in patients with high ovarian response and/or at risk for ovarian hyperstimulation syndrome (OHSS) undergoing an antagonist protocol, with 40 IU of leuprolide acetate (Lupron®, AbbVie Laboratories, Chicago, IL) concomitant with 1000–1500 IU of hCG (Novarel®, Ferring Pharmaceuticals, Parsippany, NJ). Vaginal oocyte retrieval (VOR) was performed by using transvaginal ultrasound guidance 36 hours later.
Gingold J.A., Zafman K., Rodriguez-Purata J., Whitehouse M.C., Lee J.A., Sandler B, & Copperman A.B. (2016). DO ELEVATED TSH LEVELS PREDICT EARLY PREGNANCY LOSS IN ART PATIENTS?. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 32(12), 973-976.
+ Open protocol
+ Expand
2

Elagolix vs. Ganirelix in Ovarian Stimulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All donors began their cycles with oral contraceptives for 10–14 days to lead into ovarian stimulation. Three days after discontinuing oral contraceptives, donors began daily injections of recombinant FSH (Follistim; Merck, NJ), with the initial dose ranging from 275–325 IU per day on the basis of age, FSH level, AMH level, and antral follicular count. On day 6 and then at 2–3 days intervals, serum testing of E2 and ultrasound monitoring were performed to guide recombinant FSH dosing. Once a 14-mm lead follicle was noted on ultrasound, 20 units per day of subcutaneous human chorionic gonadotropin were administered daily along with ovulation suppression; the study group received elagolix (200 mg PO QHS; Orilissa; AbbVie Inc., IL), and the historical control group received ganirelix (250 mcg, SC QHS; Merck, NJ). Elagolix or ganirelix was then discontinued 24 hours before the GnRH agonist trigger. Once follicular maturity was reached on the basis of follicular number, follicular size, and E2 levels, a GnRH agonist (4 mg SC; Lupron; AbbVie, IL) was then used to induce ovulation. Oocyte retrieval was performed 36 hours after the trigger.
Boniface C., Schnorr J.N., Gray J., McLaughlin J., Cook H., Slowey M, & Schnorr J. (2023). The role of elagolix in the suppression of ovulation in donor oocyte cycles. F&S Reports, 4(2), 179-182.
+ Open protocol
+ Expand
3

Controlled Ovarian Stimulation and ICSI

Check if the same lab product or an alternative is used in the 5 most similar protocols
Controlled ovarian stimulation was performed using recombinant FSH (Gonal-F®, Merck KGaA, Darmstadt, Germany) and pituitary suppression using a GnRH antagonist (GnRH - Cetrotide® Merck KGaA, Darmstadt, Germany). Follicular growth was monitored using transvaginal ultrasound starting on day 4 of the gonadotropin administration. When adequate follicular growth and serum E2 levels were observed, recombinant hCG (Ovidrel®, Merck KGaA, Darmstadt, Germany) or leuprolide acetate (Lupron®, AbbVie, Boston, USA) was administered to trigger the final follicular maturation. The oocytes were collected 35 hours after hCG administration through transvaginal ultrasound ovum pick-up.
The recovered oocytes were assessed to determine their nuclear status, and those in metaphase II were submitted to ICSI following routine procedures (Palermo et al., 1997 (link)).
Borges Jr. E., Mulato M.G., Souza Setti A., Iaconelli Jr. A., Vieira Geraldo M, & Paes de Almeida Ferreira Braga D. (2020). Serum microRNA profiling for the identification of predictive molecular markers of the response to controlled ovarian stimulation. JBRA Assisted Reproduction, 24(2), 97-103.
+ Open protocol
+ Expand
4

Ovarian Stimulation Protocols for IVF and Egg Donation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ovarian stimulation was performed using one of five different protocols, depending on physician preference and patient characteristics. At CRA, both egg donors and patients undergoing IVF with their own eggs (hereafter referred to as ''nondonors'') were treated with the use of a GnRH antagonist protocol with a dual trigger of hCG (Noravel, Ferring; or Pregnyl, Merck) and leuprolide acetate (21) (Lupron, Abbvie), after pretreatment with the use of oral contraceptives or oral luteal-phase 17b-E 2 (Estrace, Allergan).
At PFC, egg donors and nondonors were treated with a long-luteal GnRH-agonist protocol (22) or an antagonist protocol (23) , with or without pretreatment with oral contraceptives. Some nondonors with decreased ovarian reserve were also treated with the use of a microdose agonist ''flare'' protocol (23, 24) with or without pretreatment with oral lutealphase 17b-E 2 . Subsequently, oocytes were retrieved from all patients with at least one mature follicle 36 hours after administration of hCG.
Simon A.L., Kiehl M., Fischer E., Proctor J.G., Bush M.R., Givens C., Rabinowitz M, & Demko Z.P. (2018). Pregnancy outcomes from more than 1,800 in vitro fertilization cycles with the use of 24-chromosome single-nucleotide polymorphism-based preimplantation genetic testing for aneuploidy. Fertility and sterility, 110(1).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!